Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranexa for painful polyneuropathy in patients with coronary artery disease
NCT00832572Phase 4
Key facts
- Status
- Terminated
- Start
- Jan 2009
- Primary completion
- Jun 2009
- Countries
- 1
- Sponsor
- Gilead Sciences
- Modality
- Small Molecules
- Drugs
- ranolazine
- Conditions
- polyneuropathy
01
Overview
Phase 4, randomised, double-blind trial of ranolazine in polyneuropathy, sponsored by Gilead Sciences. Primary endpoint: Reduction in Neuropathic Pain at 6 weeks. Started Jan 2009; status: terminated.
02
Design
- Study design
- RandomizedDouble-blind
03
Who it enrols
Adults aged 18 or older with coronary artery disease and clinically diagnosed peripheral neuropathy.
04
Endpoints
Primary
Reduction in Neuropathic Pain
Secondary
Short Form 36 Health Survey Questionnaire
Beyond the preview
Go deeper on NCT00832572.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00832572.